Return to The JAM Blog

Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher

It's been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That's likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of the American Society of Hematology in San Diego. As of October 11, the […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.